A randomized, single-blind, controlled trial to evaluate the effects of neural therapy on tinnitus severity, disability, and quality of life in patients with tinnitus.
The study is planned to be conducted between December 2025 and March 2026. The sample size is 30 patients. The number of centers is 1. The study duration is 3 months.
Patients with a type A tympanogram in the tympanogram of all cases with normal otological examinations (air-bone gap should not be observed in any case).
Patients with a disease that may cause objective tinnitus,
Otosclerosis,
Chronic otitis media,
Acoustic tumor,
Parallel
Neural Therapy of Huneke
Procedure/SurgeryThe aim for tinnitus and facial pain is to regulate the trigeminal system and autonomic balance. Concentration used: Lidocaine 0.5%. The auriculotemporal, infraorbital, zygomaticotemporal, and stellate regions were targeted. Puncture applications: 0.3-0.5 mL will be administered behind the ear, around the mastoid process, behind the tragus, and in the temporomandibular region. If necessary, the stellate ganglion area can be supplemented with regulation injections. Negative aspiration and aseptic technique will be applied before each application. Transient mild dizziness or local redness may occur after application. To avoid the risk of systemic toxicity, the total dose should generally not exceed a maximum of 200 mg of lidocaine.
Betahistine 24 mg bid (Betaserc)
DrugPatients will be given Betahistine 16-48 mg/day in divided doses, depending on their weight and disease severity.
Turkish version of the Tinnitus Disability Questionnaire (THI)
SF-12 (short form)
Tinnitus severity according to VAS (visual analog scale)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
